We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Rapid COVID-19 Tests Return Minimal False Positives and Moderately High False Negatives, Finds New Study

By LabMedica International staff writers
Posted on 09 Apr 2021
A new study has found that rapid COVID-19 antigen tests have very low false positive rates but a moderately high false negative rate.

Researchers from the University of Southern California (USC; Los Angeles, CA, USA) conducted the study to see how well inexpensive, easy-to-use COVID-19 tests might work as a screening tool for schools to help them reopen safely. More...
The tests show promise for schools, especially if they use serial testing, such as twice a week.

Children arriving with their parents at a walk-up testing site during the winter surge of COVID cases were given the opportunity to be tested for COVID twice - once with a rapid antigen test and once with the “gold standard” PCR test, to confirm the results of the rapid test. Overall, 774 children ages 5 to 17 years old took both tests. The study found that the rapid antigen tests have very low false positive rates but a moderately high false negative rate. In other words, the tests rarely identified someone as positive who was not but did occasionally identify someone as negative who in fact had COVID.

Among asymptomatic children who had COVID, as measured by the PCR test, the rapid antigen test identified about 50% of COVID-19 cases. The reason the rapid antigen test failed to identify many COVID-19 cases in children was because the majority of children tested had low viral loads as measured by Ct values - the number of times one needs to amplify the test sample to detect the genetic material of the virus. The test was over 90% accurate when focused on the sample of children with high viral loads who were very likely to be infectious. The test was about 99% accurate among asymptomatic children who did not have COVID-19. That is, the test gave a false positive result in one out of 100 asymptomatic children. The researchers suggest that the rapid tests, which require inserting a swab about a half-inch up the nose, could be administered by school staff or be self-administered with supervision. In addition, serial testing could allow schools to relax social distancing rules.

“The good news is that the false negative rate is low in kids likely to be infectious, as measured by viral load,” said Neeraj Sood, who directs the COVID Initiative at the USC Schaeffer Center for Health Policy and Economics. “Serial rapid testing may help compensate for missing the virus in the earliest stage of infection. If you’re testing these kids every four days or every five days, then there’s a good chance that you will catch them when they’re infectious.”

Related Links:
University of Southern California


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.